News

A teenager with a mutation in the C3 gene developed atypical hemolytic uremic syndrome (aHUS), which manifested as bleeding in the lungs, after undergoing kidney transplant surgery. According to clinicians, a correct and timely diagnosis in a case like this is essential for improving treatment outcomes. “In patients presenting…

A delay in diagnosing and treating a woman with pregnancy-related atypical hemolytic uremic syndrome (aHUS) may have contributed to her kidney failure, a U.S. case study suggests. Her condition was first thought to be thrombotic thrombocytopenic purpura (TTP), a related blood disorder. Until she was finally diagnosed correctly…

A rare mutation in the CFHR5 gene may have led to the excessive activation of the immune complement system, triggering atypical hemolytic uremic syndrome (aHUS) in a 5-year-old girl, a case study reports. The mutation in CFHR5 (which stands for complement factor H-related protein 5) was found to reduce…

A mutation in the complement factor I (CFI) gene can lead in rare cases to both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy, two complement-mediated kidney diseases, a case study in Japan shows. “Overlapping [aHUS] and C3 glomerulopathy with complement factor I mutation is very rare, especially in…

Intensive treatment with anti-vascular endothelial growth factor (anti-VEGF) medications — commonly used to treat disorders causing vision impairments — are thought to have led to the onset of atypical hemolytic uremic syndrome (aHUS) in a man in his 40s. It is a rare finding in an extremely rare disease,…

Alexion, AstraZeneca Rare Disease signed off on a letter of intent in Canada that brings Ultomiris (ravulizumab) — approved in the country for certain people with atypical hemolytic uremic syndrome (aHUS) — a step closer to becoming available under public drug plans. The letter, to the pan-Canadian Pharmaceutical…

Both Soliris (eculizumab) and Ultomiris (ravulizumab) are safe, and have similar effectiveness in improving kidney function and blood parameters in people with atypical hemolytic syndrome (aHUS), according to a new systematic review study. However, Ultomoris “was preferred by a majority of the patients as it only has…

Complement-blocking medications like Soliris (eculizumab) can be effective for controlling atypical hemolytic uremic syndrome (aHUS) in patients carrying a genetic variant called the MCPggaac haplotype, a new study reports. Researchers in Southeastern Europe reviewed the cases of 14 children in the region with aHUS to determine the best…

Blood concentrations of Soliris (eculizumab) needed to fully suppress the immune complement cascade may be higher than previously thought in people with atypical hemolytic uremic syndrome (aHUS), according to a study from Spain. Most patients were found to have concentrations above estimated therapeutic levels in their bloodstream before…

A group of blood disorders called hypereosinophilia syndrome, known as HES, was suspected to be the trigger event that led to atypical hemolytic uremic syndrome (aHUS) in a woman in her late 30s, according to a new case study. HES is caused by an overload of eosinophils, a type…